MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

New York, New York--(Newsfile Corp. - August 5, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ: MRNS) and certain of its officers.

Class Definition:

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MRNS.

Case Details:

According to the Complaint, Marinus describes itself as a "commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone)."

The Complaint alleges that Marinus made materially false and/or misleading statements regarding its Randomized Therapy in Status Epilepticus (RAISE) trial, which the Company described as a "pivotal Phase 3 trial in refractory status epilepticus (RSE) patients." Specifically, the Company made false and/or misleading statements and/or failed to disclose that:

(1) Marinus understated the risk of failure to meet the early-stopping criteria in the RAISE trial;

(2) Marinus did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and

(3) as a result, Marinus' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

On April 15, 2024, according to the Complaint, before the market opened, Marinus issued a press release entitled "Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial results." (the "April 15 Announcement"). The April 15 Announcement revealed that the RAISE trial had not met early stopping criteria and also that the Company would implement cost-saving measures.